Cytokine modulators in the treatment of sarcoidosis

Rheumatology International

Volumn 31, Issue 12, 2011, Pages 1539-1544

  Bargagli, E ^a   Olivieri, C ^a   Rottoli, P ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Pharmacological treatments; Sarcoidosis

Indexed keywords

ADALIMUMAB; APREMILAST; CYTOKINE; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; PLACEBO; RITUXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

ALLERGIC REACTION; ASPERGILLOSIS; CLINICAL TRIAL (TOPIC); CONSTIPATION; CROHN DISEASE; CRYPTOCOCCOSIS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GRANULOMA; GRANULOMATOUS INFLAMMATION; HISTOPLASMOSIS; HUMAN; LISTERIOSIS; LUNG SARCOIDOSIS; MEDICAL LITERATURE; MEDICAL RESEARCH; MYCOBACTERIOSIS; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSORIASIS; RASH; REVIEW; SARCOIDOSIS; TERATOGENICITY; TOXIC HEPATITIS; TOXOPLASMOSIS; UVEITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; PENTOXIFYLLINE; SARCOIDOSIS, PULMONARY; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 83555166298     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-1969-9     Document Type: Review

References (88)

1. GW Hunninghake U Costabel M Ando, et al. 1999 ATS/ERS/WASOG statement on sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 16 149 173 10560120 1:STN:280:DC%2BD3c%2Fitl2isg%3D%3D (Pubitemid 29469097)
2. B Bradley HM Branley JJ Egan, et al. 2008 Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society Thorax 63 1 58 10.1136/thx.2007.086215
3. CS King W Kelly 2009 Treatment of sarcoidosis Dis Mon 55 704 718 19857644 10.1016/j.disamonth.2009.06.002
4. RP Baughman U Costabel RM Du Bois 2008 Treatment of sarcoidosis Clin Chest Med 29 533 548 18539243 10.1016/j.ccm.2008.03.012 (Pubitemid 351784486)
5. RP Baughman EE Lower 2005 Therapy for sarcoidosis Eur Respir Mon 32 301 315 10.1183/1025448x.00032020
6. NJ Sweiss j Curran RP Baughman 2007 Sarcoidosis, role of TNF inhibitors and other biological agents: past, present and future concepts Clin Dermatol 25 341 346 17560312 10.1016/j.clindermatol.2007.03.012 (Pubitemid 46856834)
7. J Muller-Quernheim 1998 Sarcoidosis: immunopathogenetic concepts and their clinical application Eur Respir J 12 716 738 9762805 10.1183/09031936.98. 12030716 1:STN:280:DyaK1cvjtlOluw%3D%3D (Pubitemid 28420156)
8. H Fehrenbach G Zissel T Goldman, et al. 2003 Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis Eur Respir J 21 421 428 12661995 10.1183/09031936.03.00083002 1:CAS:528: DC%2BD3sXis1GmtL0%3D (Pubitemid 36336199)
9. RP Baughman SA Stohofer J Buchsbaum EE Lower 1990 Release of TNF by alveolar macrophages of patients with sarcoidosis J Lab Clin Med 115 36 42 2299255 1:CAS:528:DyaK3cXhtFOju78%3D (Pubitemid 20044133)
10. MW Ziegenhagen E Rothe G Zissel J Muller Quernheim 2002 Exaggerated TNF alpha release of alveolar macrophages in corticosteroid resistant sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 19 185 190 12405487
11. MW Ziegenhagen UK Benner G Zissel P Zabel M Schlaak J Muller Quernheim 1997 Sarcoidosis: TNF α release from alveolar macrophages and serum levels of sIL-2R are prognostic markers Am J Respir Crit Care Med 156 1586 1592 9372680 1:STN:280:DyaK1c%2FjvF2nuw%3D%3D (Pubitemid 27505529)
12. E Bargagli A Mazzi P Rottoli 2008 Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum and exhaled gas Clin Chest Med 29 445 458 18539237 10.1016/j.ccm.2008.03.004 1:STN:280:DC%2BD1czntFGktA%3D%3D (Pubitemid 351778212)
13. F Sinigallia 2000 IL-12 in lung diseases Sarcoidosis Vasc Diffuse Lung Dis 17 122 124
14. K Shigehara N Shijubo M Ohmichi, et al. 2003 Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis Clin Exp Immunol 132 152 157 12653850 10.1046/j.1365-2249.2003.02105.x 1:CAS:528:DC%2BD3sXjtlKrsLk%3D (Pubitemid 36418918)
15. K Shigehara N Shijubo M Ohmichi, et al. 2001 IL12 and IL18 are increased and stimulated IFN-γ production in sarcoid lungs J Immunol 166 642 649 11123348 1:CAS:528:DC%2BD3MXis1emtA%3D%3D (Pubitemid 32038488)
16. A Belkhou R Younsi I El Bouchti S El Hassani 2008 Rituximab as a treatment alternative in sarcoidosis Joint Bone Spine 75 511 512 18562234 10.1016/j.jbspin.2008.01.025
17. M Ramos-Casals P Brito-Zeron S Munoz MJ Soto 2008 A systemic review of the off-label use of biological therapies in systemic autoimmune diseases Medicine 87 345 364 19011506 10.1097/MD.0b013e318190f170
18. T Mikuniya S Nagai N Takeuki, et al. 2000 Significance of the IL1-receptor antagonist/IL1-beta ratio as a prognostic factor in patients with pulmonary sarcoidosis Respiration 67 389 396 10940792 10.1159/000029536 1:CAS:528:DC%2BD3cXmtlSmt7g%3D (Pubitemid 30666000)
19. BJ Scallon MA More H Trinh 1995 Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 251 259 7640345 10.1006/cyto.1995.0029 1:CAS:528:DyaK2MXls1ait70%3D
20. RP Baughman EE Lower 2001 Infliximab for refractory sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 18 70 74 11354550 1:STN:280: DC%2BD3M3lsFGlsg%3D%3D (Pubitemid 32280539)
21. JD Doty JE Mazur MA Judson 2005 Treatment of sarcoidosis with infliximab Chest 127 1064 1071 15764796 10.1378/chest.127.3.1064 1:CAS:528: DC%2BD2MXjtVKgsrc%3D (Pubitemid 40775543)
22. RP Baughman M Drent MS Kavuru, et al. 2006 Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement Am J Respir Crit Care Med 174 795 802 16840744 10.1164/rccm.200603-402OC 1:CAS:528:DC%2BD28XhtFams7jK (Pubitemid 44511661)
23. S Saleh S Ghodsian V Yakimova J Henderson OP Sharma 2006 Effectiveness of infliximab in treating selected patients with sarcoidosis Respir Med 100 2053 2059 16935484 10.1016/j.rmed.2006.02.017 (Pubitemid 44514944)
24. JH Meyerle A Shoor 2003 The use of infliximab in cutaneous sarcoidosis J Drugs Dermatol 2 413 414 12884466
25. RP Baughman DA Bradley EE Lower 2005 Infliximab for ocular chronic inflammation Int J Clin Pharmacol Ther 43 7 11 15704608 1:STN:280: DC%2BD2M%2FnsFKrtg%3D%3D
26. M Sollberger F Fluri T Baumann 2004 Successful treatment of steroid-refractory neurosarcoidosis with infliximab J Neurol 251 760 761 15311358 10.1007/s00415-004-0432-1 1:STN:280:DC%2BD2cvgs1Gqtw%3D%3D (Pubitemid 38824027)
27. C Kobylecki S Shaunak 2007 Refractory neurosarcoidosis responsive to infliximab Practical Neurol 7 112 115 (Pubitemid 46578851)
28. M Moravan BM Segal 2009 Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil Neurology 72 337 340 19171830 10.1212/01.wnl.0000341278. 26993.22 1:CAS:528:DC%2BD1MXmvVKhtw%3D%3D
29. M Rossman LS Newman RP Baughman, et al. 2006 A double-blind, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 23 201 208 18038919 (Pubitemid 47596315)
30. MA Judson RP Baughman U Costabel, et al. 2008 Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomized trial Eur Respir J 31 1189 1196 18256069 10.1183/09031936.00051907 1:CAS:528:DC%2BD1cXosVWisr8%3D
31. S Agarwal S Bhagat B Dasgupta 2009 Sarcoid sacroiliitis: successful treatment with infliximab Ann Rheum Dis 68 2 283 10.1136/ard.2007.087155
32. M Sodhi K Pearson ES White DA Culver 2009 Infliximab therapy rescues cyclophosphamide failure in severe CNS sarcoidosis Respir Med 103 2 268 273 18835147 10.1016/j.rmed.2008.08.016
33. J Corbett 2009 Treating CNS sarcoidosis with infliximab and MMF Curr Neurosci Rep 9 339 340 10.1007/s11910-009-0061-2
34. N Dhingra J Morgan AD Dick 2009 Switching biological agents for uveitis Eye 23 1868 1870 19648889 10.1038/eye.2009.203 1:CAS:528:DC%2BD1MXhtFSnsb3I
35. AM Thielen C Barde JH Saurat E Laffitte 2009 Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF alpha antagonists Dermatology 219 59 62 19468200 10.1159/000221005 1:CAS:528:DC%2BD1MXosV2mtL0%3D
36. L Arnaud D Sene N Costedoat-Chalumeau, et al. 2009 Disseminated cryptococcal infection and anti-TNFalpha treatment for refractory sarcoidosis: an expected association? J Rheumatol 36 462 463 19208587 10.3899/jrheum.080426
37. MA Judson 2009 Allergic pulmonary aspergillosis and infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cytokine balance Chest 136 526 535 19395578 10.1378/chest.09-1094
38. S Josse N Klemmer S Moreno-Swirc, et al. 2009 Infliximab induced skin and pulmonary sarcoidosis in a rheumatoid arthritis patient Joint Bone Spine 76 6 718 719 19464223 10.1016/j.jbspin.2009.02.003
39. A Massara L Cavazzini R La Corte F Trotta 2010 Sarcoidosis appearing during Anti-tumor necrosis factor alpha therapy: a new "Class Effect" paradoxical phenomenon. Two case reports and literature review Semin Arthritis Rheum 39 313 319 19147181 10.1016/j.semarthrit.2008.11.003 1:CAS:528: DC%2BC3cXpslWruw%3D%3D
40. CI Daien A Monnier P Claudepierre, et al. 2009 Sarcoidosis-like granulomatosis in patients treated with TNF alpha blockers: 10 cases Rheumatology 48 883 886 19423648 10.1093/rheumatology/kep046 1:CAS:528:DC%2BD1MXht1WktLzE
41. RP Baughman R Shipley S Desai, et al. 2009 Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation Chest 136 526 535 19395578 10.1378/chest.08-1876 1:CAS:528:DC%2BD1MXhtFait77I
42. E Stagaki WK Mountford DT Lackland MA Judson 2009 The treatment of lupus pernio: results of 116 treatment courses in 54 patients Chest 135 2 468 476 18812454 10.1378/chest.08-1347
43. LW Moreland MH Schiff SW Baumgartner 1999 Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial Ann Intern Med 130 478 486 10075615 1:CAS:528:DyaK1MXitFChs7Y%3D (Pubitemid 29135800)
44. D Khanna M Liebling JS Louise 2003 Etanercept ameliorates sarcoidosis arthritis and skin disease J Rheumatol 30 1864 1867 12913948 (Pubitemid 36962468)
45. JP Utz AH Limper S Kalra, et al. 2003 Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis Chest 124 177 185 12853521 10.1378/chest.124.1.177 1:CAS:528:DC%2BD3sXmsFCltrY%3D (Pubitemid 36851350)
46. RP Baughman EE Lower DA Bradley LA Raymond A Kaufman 2005 Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial Chest 128 1062 1067 16100213 10.1378/chest.128.2.1062 (Pubitemid 41140552)
47. K Hobbs 2005 Chronic sarcoid arthritis treated with intraarticular etanercept Arthritis Rheum 52 987 988 15751067 10.1002/art.20936 (Pubitemid 40365126)
48. NJ Sweiss MJ Welsch JJ Curran MH Ellman 2005 Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis Arthritis Rheum 53 788 791 16208666 10.1002/art.21468 1:CAS:528:DC%2BD2MXhtF2jtLrN (Pubitemid 41463847)
49. J Suzuki H Goto 2009 Uveitis associated with sarcoidosis exacerbated by etanercept therapy Jpn J Ophthalmol 53 4 439 440 19763766 10.1007/s10384-009- 0691-6
50. AM Thielen C Barde JH Saurat E Laffitte 2009 Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists Dermatology 219 1 59 62 19468200 10.1159/000221005 1:CAS:528:DC%2BD1MXosV2mtL0%3D
51. Skoie IM, Wildhagen K, Omdal R (2010) Development of sarcoidosis following etanercept treatment: a report of 3 cases. Rheumatol Int (in press)
52. S Takatori Y Kamata T Murosaki, et al. 2010 Abrupt development of sarcoidosis with a prodromal increase in plasma osteopontin in a patient with rheumatoid arthritis during treatment with etanercept J Rheumatol 37 1 210 211 20040649 10.3899/jrheum.090647
53. M Samimi G Lorette L Machet, et al. 2009 Facial granulomatous nodules during etanercept treatment for psoriasis Int J Dermatol 48 9 1025 1027 19703000 10.1111/j.1365-4632.2009.04080.x
54. DE Baker 2004 Adalimumab: human recombinant immunoglobulin G1 anti-tumor necrosis factor monoclonal antibody Rev Gastroenterol Disord 4 196 210 15580154 (Pubitemid 40012219)
55. MA Philips J Lynch FH Azmi 2005 Ulcerative cutaneous sarcoidosis responding to adalimumab Acad Dermatol 53 917 10.1016/j.jaad.2005.02.023 (Pubitemid 41501405)
56. MP Hefferman DI Smith 2006 Adalimumab for treatment of cutaneous sarcoidosis Arch Dermatol 142 17 19 10.1001/archderm.142.1.17 (Pubitemid 43107354)
57. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN (2006) Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 25:596-597 (Pubitemid 44137652)
58. SR Patel 2009 Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report J Med Case Reports 3 8573 19830230 10.4076/1752-1947-3-8573
59. M Cufí-Benet C Sabadell O Codina 2010 Adalimumab in the treatment of parotid sarcoidosis Arch Bronconeumol 46 49 50 19656610 10.1016/j.arbres. 2009.06.002
60. M Marnane T Lynch J Scott, et al. 2009 Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab J Neurol 256 1 139 140 19219574 10.1007/s00415-009-0077-1
61. SK Metyas RM Tadros DG Arkfeld 2009 Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis Rheumatol Int 29 4 437 439 18762943 10.1007/s00296-008-0691-8 1:STN:280:DC%2BD1M7hsFynuw%3D%3D
62. F Dhaille V Viseux A Caudron, et al. 2010 Cutaneous sarcoidosis occurring during anti-TNFalpha treatment: reporting of two cases Dermatology 220 234 237 20185892 10.1159/000275676 1:STN:280:DC%2BC3c3pt1Wktg%3D%3D
63. Gifre L, Ruiz-Esquide V, Xaubet A et al (2011) Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch Bronchoneumol 47:208-212
64. SA Antoniu 2010 Targeting the TNF alpha pathway in sarcoidosis Expert Opin Ther Targets 14 21 29 20001207 10.1517/14728220903449244 1:CAS:528:DC%2BD1MXhsFCitbvN
65. P Schafer A Parton A Gandhi, et al. 2010 Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis Br J Pharmacol 159 4 842 855 20050849 10.1111/j.1476-5381.2009.00559.x 1:CAS:528:DC%2BC3cXjtF2hs7Y%3D
66. L Statkute EM Ruderman 2010 Novel TNF antagonists for the treatment of rheumatoid arthritis Expert Opin Investig Drugs 19 105 115 20001558 10.1517/13543780903438559 1:CAS:528:DC%2BD1MXhsFCiu77I
67. ER Soriano J Rosa 2009 Update on the treatment of peripheral arthritis in psoriatic arthritis Curr Rheumatol Rep 11 270 277 19691930 10.1007/s11926-009- 0038-9 1:CAS:528:DC%2BC3cXhtFeku7vL
68. SA Antoniu 2009 Golimumab for severe asthma Expert Opin Investig Drugs 18 1421 1423 19678804 10.1517/13543780903136716 1:CAS:528:DC%2BD1MXpslOlur8%3D
69. JL Tavares A Wangoo P Dilworth, et al. 1997 Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages Respir Med 91 31 39 9068814 10.1016/S0954-6111(97)90134-7 1:STN:280:DyaK2s3itFOlug%3D%3D (Pubitemid 27105519)
70. Q Ye B Chen Z Tong, et al. 2006 Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease Eur Respir J 26 824 831 10.1183/09031936.06.00131505 (Pubitemid 46335531)
71. M Carlesimo S Giustini A Rossi P Bonaccorsi S Calvieri 1995 Treatment of cutaneous and pulmonary sarcoidosis with thalidomide J Am Acad Dermatol 32 866 869 7722046 10.1016/0190-9622(95)91549-4 1:STN:280:DyaK2M3jvVKmtA%3D%3D
72. RP Baughman MA Judson AS Teirstein DR Moller EE Lower 2002 Thalidomide for chronic sarcoidosis Chest 122 227 232 12114363 10.1378/chest.122.1.227 1:CAS:528:DC%2BD38XmtF2is7g%3D (Pubitemid 34754167)
73. MA Judson J Silvestri C Hartung T Byars CE Cox 2006 The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 23 51 57 16933470 (Pubitemid 44259209)
74. JB Marriott K Dredge AG Dalgreish 2003 Thalidomide derived immunomodulatory drugs (ImiDs) as potential therapeutic agents Curr Drug Targets Immune Endocr Metabol Disord 3 181 186 12871024 10.2174/1568008033340207 1:CAS:528:DC%2BD3sXmvFahu78%3D
75. K Yasui M Yashiro M Tsuge, et al. 2010 Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism Arthritis and Rheum 62 250 257 10.1002/art.25035 1:CAS:528: DC%2BC3cXhtFGnurfK
76. LJ Marques L Zheng N Poulakis J Guzman U Costabel 1999 Pentoxifylline inhibits TNFα production from alveolar macrophages Am J Respir Crit Care Med 159 508 511 9927365 1:STN:280:DyaK1M7is1KksA%3D%3D (Pubitemid 29084873)
77. Z Tong H Dai B Chen Z Abdoh J Guzman U Costabel 2004 Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone Chest 124 1526 1532 10.1378/chest.124.4.1526 (Pubitemid 37290067)
78. P Zabel P Entzian K Dalhoff M Schlaak 1997 Pentoxifylline in treatment of sarcoidosis Am J Crit Care Med 155 1665 1669 1:STN:280:DyaK2s3pvFOhtg%3D%3D (Pubitemid 27216674)
79. Manganiello VC, Park MK, Stylianou M et al (2005) A randomized trial of pentoxifylline in pulmonary sarcoidosis. American Thoracic Society 2005 international conference, 20-25 May. San Diego, California, p A14
80. M Elliott J Benson M Blank, et al. 2009 Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases Ann N Y Acad Sci 1182 97 110 20074279 10.1111/j.1749-6632.2009.05070.x 1:CAS:528: DC%2BC3cXhs1KrsL0%3D
81. CE Griffiths BE Strober P van de Kerkhof, et al. 2010 Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 118 128 20071701 10.1056/NEJMoa0810652 1:CAS:528:DC%2BC3cXnsFGjtA%3D%3D
82. NH Shear J Prinz K Papp RG Langley WP Gulliver 2008 Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease J Cutan Med Surg 12 s1 s10 19886505 1:CAS:528:DC%2BD1MXps1Gqsg%3D%3D
83. EW St. Clair 2009 Novel targeted therapies for autoimmunity Curr Opin Immunol 21 648 657 19828300 10.1016/j.coi.2009.09.008 1:CAS:528: DC%2BD1MXhsVKntbzP
84. A Belkhou R Younsi I El Bouchti, et al. 2008 Rituximab as a treatment alternative in sarcoidosis Joint Bone Spin 75 511 512 10.1016/j.jbspin.2008.01. 025
85. J Gottemberg L Guillevin O Lambotte, et al. 2005 Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases Ann Rheum Dis 64 913 920 10.1136/ard.2004.029694 (Pubitemid 40733918)
86. V Dasilva V Breuil P Chevallier, et al. 2010 Relapse of severe sarcoidosis with an uncommon peritoneal location after TNF alpha blockade. Efficacy of rituximab, report of a single case Joint Bone Spine 77 82 20022779 10.1016/j.jbspin.2009.11.005
87. A Régent L Mouthon 2009 Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases Presse Med 38 5 761 773 19349142 10.1016/j.lpm.2009.02.006
88. RP Baughman EE Lower M Drent 2008 Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them Sarcoidosis Vasc Diffuse Lung Dis 25 2 76 89 19382527 1:STN:280:DC%2BD1M3ptFOhtQ%3D%3D